dc.contributor
Institut Català de la Salut
dc.contributor
[Wirth LJ] Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. [Brose MS] Sidney Kimmel Cancer Center of Jefferson University Health, Philadelphia, PA, USA. [Elisei R] Endocrine Unit, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy. [Capdevila J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB Quirón-Teknon, Barcelona, Spain. [Hoff AO] Department of Endocrinology, Endocrine Oncology Unit, Instituto de Cancer do Estado de Sao Paulo, Sao Paulo, Brazil. [Hu MI] Department of Endocrine Neoplasia & Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Wirth, Lori J.
dc.contributor.author
Brose, Marcia S
dc.contributor.author
Hoff, Ana
dc.contributor.author
Hu, Mimi
dc.contributor.author
Capdevila Castillon, Jaume
dc.contributor.author
Elisei, Rossella
dc.date.accessioned
2025-10-25T05:38:21Z
dc.date.available
2025-10-25T05:38:21Z
dc.date.issued
2022-10-26T12:31:11Z
dc.date.issued
2022-10-26T12:31:11Z
dc.identifier
Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, et al. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer. Future Oncol. 2022 Sep;18(28):3143–50.
dc.identifier
https://hdl.handle.net/11351/8353
dc.identifier
10.2217/fon-2022-0657
dc.identifier.uri
http://hdl.handle.net/11351/8353
dc.description.abstract
Medullary thyroid cancer; Selpercatinib; Targeted therapy
dc.description.abstract
Cáncer medular de tiroides; Selpercatinib; Terapia dirigida
dc.description.abstract
Càncer medul·lar de tiroide; Selpercatinib; Teràpia dirigida
dc.description.abstract
Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with RET-mutant medullary thyroid cancer (MTC). LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled, phase III trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced/metastatic RET-mutant MTC. The primary objective is to compare progression-free survival (per RECIST 1.1) by blinded independent central review of patients with progressive, advanced, multikinase inhibitor-naive, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib. Key secondary objectives are to compare other efficacy outcomes (per RECIST 1.1) and tolerability of selpercatinib versus cabozantinib or vandetanib.
dc.format
application/pdf
dc.publisher
Future Medicine
dc.relation
Future Oncology;18(28)
dc.relation
https://doi.org/10.2217/fon-2022-0657
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Proteïnes quinases - Inhibidors - Efectes secundaris
dc.subject
Tiroide - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors
dc.subject
Other subheadings::Other subheadings::Other subheadings::/adverse effects
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
dc.title
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
